Abstract
Resistance to antiepileptic drugs (AED) remains a major problem in clinical epileptology. This pharmacoresistance is independent of the choice of AEDs. Different hypotheses have been proposed to explain the neurobiological basis for pharmacoresistance in epilepsy. The transporter hypothesis is the mostly investigated theory. Hereby, overexpression of multidrug efflux transporters, such as P-glycoprotein (Pgp), at the blood-brain-barrier (BBB) is thought to be involved in pharmacoresistance in epilepsy by extruding AEDs from their target site. Accumulating evidence supports an overexpression of Pgp in pharmacoresistant epilepsy. Molecular Imaging studies provide unique opportunities for the in-vivo study of the transporter hypothesis in the central nervous system (CNS). Several studies demonstrated that positron emission tomography (PET) with [11C]-radiolabled Pgp substrates is a promising tool for in vivo investigation of Pgp function at the rat, monkey and human BBB. Quantification of Pgp over activity in epilepsy patients by in vivo imaging could be highly useful because altered treatment strategies or novel AED could then be applied.
Keywords: Blood-brain-barrier, P-glycoprotein, positron emission tomography, drug transporter, epilepsy.
Current Pharmaceutical Design
Title:ABC Transporters and Drug Resistance in Patients with Epilepsy
Volume: 22 Issue: 38
Author(s): Maria Feldmann and Matthias Koepp
Affiliation:
Keywords: Blood-brain-barrier, P-glycoprotein, positron emission tomography, drug transporter, epilepsy.
Abstract: Resistance to antiepileptic drugs (AED) remains a major problem in clinical epileptology. This pharmacoresistance is independent of the choice of AEDs. Different hypotheses have been proposed to explain the neurobiological basis for pharmacoresistance in epilepsy. The transporter hypothesis is the mostly investigated theory. Hereby, overexpression of multidrug efflux transporters, such as P-glycoprotein (Pgp), at the blood-brain-barrier (BBB) is thought to be involved in pharmacoresistance in epilepsy by extruding AEDs from their target site. Accumulating evidence supports an overexpression of Pgp in pharmacoresistant epilepsy. Molecular Imaging studies provide unique opportunities for the in-vivo study of the transporter hypothesis in the central nervous system (CNS). Several studies demonstrated that positron emission tomography (PET) with [11C]-radiolabled Pgp substrates is a promising tool for in vivo investigation of Pgp function at the rat, monkey and human BBB. Quantification of Pgp over activity in epilepsy patients by in vivo imaging could be highly useful because altered treatment strategies or novel AED could then be applied.
Export Options
About this article
Cite this article as:
Feldmann Maria and Koepp Matthias, ABC Transporters and Drug Resistance in Patients with Epilepsy, Current Pharmaceutical Design 2016; 22 (38) . https://dx.doi.org/10.2174/1381612822666160810150416
DOI https://dx.doi.org/10.2174/1381612822666160810150416 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Ethanolamine: A Potential Promoiety with Additional Effects on the Brain
CNS & Neurological Disorders - Drug Targets Meet the Editorial Board Member
CNS & Neurological Disorders - Drug Targets Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Cellular and Network Mechanisms Underlying Memory Impairment Induced by Amyloid β Protein
Protein & Peptide Letters “Micromanaging” Glioblastoma Multiforme: The Potential of MicroRNAs, Circular RNAs, and the Hippo Pathway as Novel Treatment Strategies
Current Neurovascular Research Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Targeting the Cholinergic System for Neuroprotection and/or Enhancement of Functional Recovery Following Neurotrauma
Current Pharmaceutical Design Season of Birth Effects on Reproduction in Women
Current Women`s Health Reviews Clinical Improvement and Cortical Adaptations After Functional Electrical Stimulation in Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets The Role of Extracellular Adenosine in Chemical Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical Aspects
Current Topics in Medicinal Chemistry Applied Computational Techniques on Schizophrenia Using Genetic Mutations
Current Topics in Medicinal Chemistry MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Editorial [Hot Topic: Analysis of Progenitor Cells in the Brain before and after Treatment (Guest Editors: M.A. Curtis and L. Paulson)]
Current Pharmaceutical Biotechnology Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Comprehensive Assessment of ADMET Risks in Drug Discovery
Current Pharmaceutical Design